Zimmer Biomet exec exercises 9,414 RSUs

Zimmer Biomet Holdings executive Yi Sang, Group President, Asia Pacific, reported the exercise and conversion of restricted stock units into common stock.

Rhea-AI Filing Summary

Zimmer Biomet Holdings executive Yi Sang, Group President, Asia Pacific, reported the exercise and conversion of restricted stock units into common stock. On March 6, 2026, he exercised a total of 9,414 restricted stock units, receiving an equal number of common shares.

Following these transactions, Yi Sang directly owned 32,251 shares of common stock. The restricted stock units converted at no cash exercise price, reflecting the vesting of equity-based compensation rather than open-market purchases or sales.

Insider Trade Summary

9,414 shares exercised/converted

Exercise 4 txns

Insider Yi Sang

Role Group President, Asia Pacific

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	7,050	$0.00	$0.00
Exercise	Restricted Stock Units	2,364	$0.00	$0.00
Exercise	Common Stock	7,050	$0.00	$0.00
Exercise	Common Stock	2,364	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 0 contracts (Direct); Common Stock — 32,251 shares (Direct)

Footnotes (1)

1. F1. Each RSU represents a contingent right to receive one share of Company common stock.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Zimmer Biomet (ZBH) executive Yi Sang report in this Form 4?

Yi Sang reported exercising and converting restricted stock units into common stock. On March 6, 2026, he acquired 9,414 common shares through RSU exercises, reflecting vesting of equity compensation rather than open-market trading activity.

How many Zimmer Biomet (ZBH) shares did Yi Sang acquire through RSU exercises?

He acquired 9,414 shares of Zimmer Biomet common stock. These came from exercising restricted stock units, with each RSU representing a contingent right to receive one share of common stock upon vesting and settlement.

What is Yi Sang’s Zimmer Biomet (ZBH) share ownership after these transactions?

After the reported transactions, Yi Sang directly held 32,251 shares of Zimmer Biomet common stock. This figure reflects his updated ownership following the conversion of restricted stock units into common shares on March 6, 2026.

Were there any open-market buys or sells by Yi Sang in Zimmer Biomet (ZBH)?

No open-market purchases or sales were reported. The Form 4 only shows derivative code M transactions, meaning exercises and conversions of restricted stock units into common stock, not discretionary buying or selling in the market.

What does each restricted stock unit (RSU) in this Zimmer Biomet (ZBH) filing represent?

Each RSU represents a contingent right to receive one share of Zimmer Biomet common stock. Upon vesting and settlement, the RSUs convert into an equivalent number of common shares, as disclosed in the filing’s footnote.

Does Yi Sang still hold any Zimmer Biomet (ZBH) derivative awards after these transactions?

No remaining derivative positions are shown in the derivative summary. The filing indicates RSUs totaling 9,414 units were exercised and converted, with no additional derivative securities listed as outstanding in this specific report.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/10/2026 - 04:08 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Yi Sang

(Last) (First) (Middle)

345 E. MAIN STREET

(Street)

WARSAW IN 46580

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ZIMMER BIOMET HOLDINGS, INC. [ ZBH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Group President, Asia Pacific

3. Date of Earliest Transaction (Month/Day/Year)
03/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/06/2026		M		7,050	A	$0	29,887	D
Common Stock	03/06/2026		M		2,364	A	$0	32,251	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	03/06/2026		M			7,050	03/06/2026	03/06/2026	Common Stock	7,050	$0	0	D
Restricted Stock Units	(1)	03/06/2026		M			2,364	03/06/2026	03/06/2026	Common Stock	2,364	$0	0	D

Explanation of Responses:

1. Each RSU represents a contingent right to receive one share of Company common stock.

	/s/ Matthew R. St. Louis, Attorney-in-Fact for Sang Yi (power of attorney previously filed)	03/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.